My research interest is in developing personalized therapies for brain cancer, through the advanced investigation of the molecular features of cancer. This expertise, together with Dr Sarah Best (personalised oncology) and Dr Jim Whittle (clinical) provides the multidisciplinary foundations of the Brain Cancer Research Laboratory.
The research interests of the lab include:
England, University College London, MStatSci, 2010
Germany, University of Göttingen, PhD, 2014
2023, MRFF, Australian Brain Cancer Mission
2023, Victorian Cancer Council, Venture Grant
2022, Lab funding, Carrie’s Beanies for Brain Cancer
2021, Near miss grant, Western Australia Department of Health
2020, Near miss grant, Western Australia Department of Health
2019, Ideas Grant, NHMRC
Chair, Bioconductor Code of Conduct Committee, 2020-ongoing
F1000 Guest Advisor, Collection “Single Cell RNA-Sequencing”, 2023
Ambassador, promoting the importance of higher mathematical and statistical education to girls, ChooseMaths, 2016-2018
1. Herring CA, Simmons RK, FREYTAG S, Poppe D, Moffet JJ, Pflueger J, … , Lister R. (2022). Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution. Cell, 185(23), 4428-4447.
2. FREYTAG S, Lister R. schex avoids overplotting for large single-cell RNA-sequencing datasets. Bioinformatics. 2019. PMID: 31794001
3. Tian L, Dong X, FREYTAG S, Lê Cao K-A,Su S, JalalAbadi A, Amann-Zalcenstein D, Weber T S, Seidi A, Jabbari J S, Naik S H, Ritchie Matthew E. scRNA-seq mixology: towards better benchmarking of single cell RNA-seq analysis methods. Nature Methods. 2019. 16(6):479-487. PMID: 31133762
4. FREYTAG S, Tian L, Lönnstedt I, Ng M, Bahlo M. Comparison of clustering tools in R for medium-sized 10x Genomics single-cell RNA-sequencing data. F1000Research. 2018. PMID: 30228881
5. FREYTAG S, Burgess R, Oliver KL, Bahlo M. brain-coX: investigating and visualising gene co-expression in seven human brain transcriptomic datasets. Genome Medicine. 2017. 9(1):55. PMID: 28595657
We use a variety of spatial technologies to investigate the tumour microenvironment, including transcriptomics and metabolomics, to better understand the architecture of glioma.
Venture Grant funding: ‘Brightest cancer researchers’: WEHI teams awarded new funding grants
Team members: Jurgen Kriel, Joel Moffet, Lutz Freytag, Tianyao Lu
The lab uses a variety of genomic techniques with a strong focus on technologies that can resolve cellular complexity, such as single cell transcriptomics, spatial transcriptomics, Nanostring and MIBIscope.
Project resource: GLIMMER funding
Team members: Oluwaseun Fatunla, Montana Spiteri
Our lab is developing a strong foundation of pre-clinical models to study glioma development in immune-competent systems with an intact blood brain barrier.
Team member: Shannon Oliver
Our lab generates patient derived models (eg. neuropshere, and patient derived xenografts) to test new anti-cancer agents and combinations.
Team members: Adam Valkovic, Zac Moore, Montana Spiteri
Our lab is intimately involved with the Australia-first perioperative clinical trial program for brain cancer, and is leading the translational research for these studies.
Team member: Rob Tobler
Correct brain development is critically dependent on genetic and environmental cues and signals. When the process goes wrong it can result in malformations of cortical development and cause severe epilepsy, often requiring surgical resection of the affected brain regions. Exploiting technologies that allow the characterization of individual cells, Saskia, and her collaborators at MCRI are investigating how epilepsy arises.